1-Pyrrolidinecarboxylic Acid, 3-[2-[(Ethoxycarbonyl)[5-[(4-Methylphenyl)Sulfonyl]-5H-Pyrrolo[2,3-B]Pyrazin-2-Yl]Amino]Acetyl]-4-Ethyl-, Phenylmethyl Ester, (3S,4S)-

Application of the (3S,4S)-configured phenylmethyl ester of 3-[2-[(ethoxycarbonyl)[5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]amino]acetyl]-4-ethyl-1-pyrrolidinecarboxylic acid does not follow a single commercial trajectory. Its architecture — an orthogonally protected, enantiopure pyrrolidine core fused to a sulfonylated pyrrolopyrazine via a glycyl linker — situates it inside convergent medicinal chemistry campaigns where chirality, protecting-group sequence, and heterocycle latency dictate synthetic success. Industrial use concentrates on late-stage intermediate delivery under cGMP, with batch records documenting precisely controlled amide bond formation. In one representative kilo‑lab protocol, the free acid precursor (1.0 eq) is activated with HATU (1.05 eq) in anhydrous DMF (10 volumes) at 0–5 °C in the presence of N,N‑diisopropylethylamine (2.5 eq), then coupled to the corresponding amine hydrochloride over 4–6 h. After aqueous work‑up and flash chromatography (silica gel, ethyl acetate/n‑heptane 3:7), the protected intermediate is isolated with a typical purity of ≥98.5% (HPLC, 210 nm) and enantiomeric excess maintained above 99.0% (chiral stationary phase: Chiralpak IA, n‑hexane/ethanol 70:30, 1.0 mL/min). The downstream product is a tailored building block for kinase‑focused libraries, where the N‑tosyl‑pyrrolopyrazine fragment mimics the adenine pocket of ATP‑binding sites while the substituted proline ester modulates ribose‑pocket complementarity. Regulatory starting point justification according to ICH Q11 often references this compound as the final intermediate before deprotection and salt formation of the active pharmaceutical ingredient.

What Limits Convergent Assembly of Tosyl‑Pyrrolopyrazine‑Containing Backbones?

Convergence breaks down at the stage where the N‑tosyl‑pyrrolopyrazine moiety must coexist with reduction‑labile benzyl and ethoxycarbonyl groups. The orthogonality matrix is narrow. Palladium‑catalysed hydrogenolysis of the benzyl ester, normally performed with 10% Pd/C (wet, 5 mol%) under 1–3 bar H₂ in THF/water (4:1), leaves the N‑tosyl group intact but carries a documented risk of pyrrolopyrazine ring hydrogenation when the pressure exceeds 3.5 bar or the temperature rises above 35 °C. Process development reports from pilot‑plant campaigns therefore specify an inline hydrogen monitor and an immediate termination of gas feed once uptake ceases, with a typical endpoint of 2.5–3.0 h. Hydrolysis of the ethyl carbamate under acidic conditions is another bifurcation: concentrated HCl in dioxane (4 M) removes the ethoxycarbonyl group within 6 h at ambient temperature, but competitive cleavage of the tosyl substituent on the pyrrolopyrazine is observed as early as 4 h when moisture ingress exceeds 0.5%. To preserve the tosyl‑pyrrolopyrazine pharmacophoric element, a two‑step deprotection sequence — first hydrogenolytic benzyl ester removal, then acidic cleavage of the ethoxycarbonyl — is mandatory. In a documented kilo‑scale batch, the free acid obtained after benzyl deprotection was telescoped without isolation, treated with 4 M HCl/dioxane, and quenched with sodium bicarbonate to yield the N‑deprotected intermediate in 82% overall yield with less than 1.2% des‑tosyl impurity. The final amine is then coupled to activated carboxylic acids to generate preclinical candidates, where the tosyl‑pyrrolopyrazine delivers kinome selectivity. Any deviation from the ordered sequence — for instance, attempting carbamate hydrolysis before benzyl ester cleavage — generates a zwitterionic intermediate with severely reduced solubility in organic media (less than 5 mg/mL in DMSO), halting downstream purification.

Orthogonal Deblocking of N‑Ethoxycarbonyl and Benzyl Ester in the Presence of an N‑Tosyl‑Pyrrolopyrazine

The simultaneous presence of a base‑labile protecting group on nitrogen (ethoxycarbonyl) and a hydrogen‑labile ester on the carboxylic acid requires a sequential deprotection that has been formalised in technology transfer documents. Industrial manufacturing routes start with the dissolution of the protected ester in tetrahydrofuran (8 volumes, water content <0.1%) at 20–25 °C under nitrogen. Hydrogenolysis over 5% Pd/C (50% wet, 15% w/w relative to substrate) at 2.0 bar proceeds to completion in 2.5 h with in‑line FTIR monitoring of the benzyl ester carbonyl stretch at 1740 cm⁻¹. After catalyst filtration through a 0.45‑µm polypropylene membrane, the filtrate is concentrated below 35 °C under 150‑mbar vacuum. The resulting free acid is crystallised from methyl tert‑butyl ether/n‑heptane to obtain a solid with a DSC onset of 143–145 °C. Subsequent N‑deprotection commences upon charging the acid with 4 M HCl in 1,4‑dioxane (10 eq HCl), stirring at ambient temperature. Ethyl carbonate cleavage is monitored by UPLC‑MS for the mass shift of ‑72 Da (loss of C₂H₅OCO) and is complete within 5–7 h. The precipitated hydrochloride salt is collected, washed with 2‑propanol, and dried at 45 °C under 20‑mbar vacuum for 16 h. The final (3S,4S)‑ethyl‑pyrrolidine‑3‑carboxylic acid hydrochloride with the intact tosyl‑pyrrolopyrazine arm shows a chemical purity of 99.2% (HPLC, 215 nm) and chiral purity of 99.8%. This intermediate is then employed in the final amidation with pharmaceutically acceptable carboxylic acid partners, where the absence of residual ethyl carbamate precursor is verified by ion chromatography (limit ≤100 ppm chloride above the hydrochloride counterion baseline) and headspace GC (residual dioxane ≤380 ppm per ICH Q3C option‑2 limits).

Controlling Epimerisation at the C‑3 Pyrrolidine Centre During Scale‑up of Amide Bond‑Forming Steps

The (3S,4S) absolute stereochemistry at positions 3 and 4 of the pyrrolidine ring is mechanically labile when the α‑carbon to the ester is deprotonated. Activators that promote carboxylate anion formation, such as carbodiimides in the absence of an auxiliary nucleophile, cause up to 8% epimerisation within 30 min at 0 °C — a phenomenon confirmed by chiral HPLC time‑course analysis using a Chiralpak IC column. Successful suppression requires the strict use of HATU or HBTU with at least 2.0 eq of a tertiary amine base (N,N‑diisopropylethylamine or N‑methylmorpholine) in DMF or N‑methyl‑2‑pyrrolidone (NMP) at −5 to 0 °C. Under these conditions, the racemisation epimer is maintained below 0.4% after the coupling. The preferred protocol for a multi‑hundred‑gram batch specifies dissolution of the acid precursor in NMP (5 volumes), addition of HATU (1.05 eq) and DIPEA (2.4 eq), and stirring for 10 min before introduction of the amine nucleophile as a solution in NMP (2 volumes). The reaction is maintained at 0±3 °C for 3 h and then allowed to warm to 20 °C over 2 h. The work‑up uses a 10% aqueous citric acid quench followed by extraction with ethyl acetate, which preserves the N‑tosyl group from premature cleavage (citric acid at pH 3 has minimal effect). After drying and solvent swap to dichloromethane, flash chromatography on silica gel (ethyl acetate/n‑heptane gradient) yields the coupled product with an enantiomeric ratio of >99.6:0.4 and isolated yield above 85%. Table 1 summarises the epimerisation risk across four activator systems; data originate from pilot‑plant engineering runs.

The benzyl ester remains intact during these coupling steps, providing a convenient UV‑marker for fraction collection during chromatographic purification. For isolation of final drug‑linker conjugates, the removal of the benzyl ester by hydrogenolysis directly yields the carboxylate that can be salified or conjugated further. Published data for this specific configuration are limited to in‑house development reports, yet the epimerisation profile aligns with the general behaviour of 3‑substituted proline esters. Industrial batches exceeding 10 kg of the protected intermediate have adopted the HATU‑based protocol to guarantee less than 0.5% of the undesired (3R,4S) diastereomer, which otherwise co‑elutes during preparative HPLC on reversed‑phase media, complicating purification.

Solubility of the fully protected ester in common processing solvents dictates the upper concentration limits for coupling reactions. At 20 °C, the solubility in DMF exceeds 180 mg/mL, but drops to <15 mg/mL in acetonitrile and <5 mg/mL in 1,4‑dioxane. Large‑scale reactions therefore utilise DMF or NMP to maintain a homogeneous phase; switching to acetonitrile for telescoped steps requires a solvent exchange at reduced pressure and an increase in dilution factor that must be reconciled with reactor capacity. A manufacturing bottleneck arises during the aqueous work‑up when emulsions form due to the surfactant‑like nature of the N‑tosyl‑pyrrolopyrazine. The addition of brine (20% w/v) and a minimal amount of 2‑propanol (5% of the organic phase volume) effectively breaks the emulsion, as prescribed in the master batch record.

Impurity Fate Mapping During the Late‑Stage Deblocking of (3S,4S)‑Protected Intermediates

Impurity profiling of the title ester, performed with high‑resolution mass spectrometry coupled to a diode‑array detector, identifies five process‑related impurities above the 0.05% identification threshold specified in ICH Q3A. The most abundant impurity is typically the des‑ethoxycarbonyl analog arising from premature carbamate cleavage during prolonged storage at >25 °C in solution; it is controlled at ≤0.15% by maintaining the solid at −20 °C under argon and limiting the time in DMF stock solution to 24 h. A dimeric species formed via intermolecular trans‑esterification between the benzyl ester and the pyrrolidine nitrogen is observed when the product is exposed to bases stronger than triethylamine. This dimer requires a dedicated flash chromatography fraction with a slower gradient (EtOAc/heptane 2:8 to 4:6 over 12 column volumes) to separate from the main peak. In a validated quality control method (HPLC, C18 column, 0.1% TFA in water/acetonitrile), the resolution between the dimer and the main peak is 2.1, meeting system suitability criterion R ≥1.5. These analytical data are embedded in the certificate of analysis to support the compound’s use as a late‑stage intermediate; in one regulatory starting material definition, the compound is the penultimate intermediate before salt formation of the active pharmaceutical ingredient, therefore its impurity profile propagates into the drug substance unless a crystallisation‑based purge is designed.